The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Withdrawal Reactions Associated with Venlafaxine
Abstract
OBJECTIVE: The aim of this paper is to describe discontinuation syndromes associated with abrupt and tapered withdrawal fo venlafaxine, and to document that withdrawal symptoms may occur after missing a single dose. CLINICAL PICTURE: We report on two patients prescribed venlafaxine. One developed a broad range of serious side effects after reaching a dose of 300 mg a day, and a severe withdrawal syndrome (including hallucinations) during a slow taper regime. The second had severe discontinuation symptoms during and aborting a slow taper regime, and described withdrawal responses after missing a single dose of venlafaxine. CONCLUSIONS: As for the short-acting selective serotonin re-uptake inhibitors, severe discontinuation reactions may occur with venlafaxine, seemingly marked most distinctly by headache, nausea, fatigue, dizziness and dysphoria, and may make cessation of the drug extremely difficult. Two strategies for addressing the concern are considered.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“suggesting a disconnect between mechanisms of possible tolerance and withdrawal [32].”
Citations
Cites
Journal of Clinical Psychiatry
(2018) · Journal of Clinical Psychiatry · doi:10.5505/kpd · Cited by 13,651
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.6.705 · Cited by 1,342
Serotonin Reuptake Inhibitor Withdrawal
Coupland, N. J., Bell, C. J., & Potokar, J. P. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199610000-00003 · Cited by 303
Clerc, G. E., Ruimy, P., & Verdeau-Paillès, J. (1994) · International Clinical Psychopharmacology · doi:10.1097/00004850-199409000-00001 · Cited by 298
(1997) · PubMed · Cited by 149
Clinical management of antidepressant discontinuation.
Rosenbaum, J. F., & Zajecka, J. (1997) · PubMed · Cited by 99
Serotonin Reuptake Inhibitor Discontinuation Syndrome: A Hypothetical Definition
Schatzberg, A. F., Haddad, P. M., Kaplan, E. M., Lejoyeux, M., Rosenbaum, J. F., Young, A. H., & Zajecka, J. (1997) · The Journal of Clinical Psychiatry · Cited by 82
Open Treatment of Obsessive-Compulsive Disorder With Venlafaxine: A Series of Ten Cases
Rauch, S. L., O'Sullivan, R. L., & Jenike, M. A. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199602000-00017 · Cited by 79
Serotonin syndrome produced by a combination of fluoxetine and lithium
Muly, E. C., McDonald, W. M., Steffens, D. C., & Book, S. (1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.10.1565 · Cited by 62
Possible venlafaxine withdrawal syndrome
Farah, A., & Lauer, T. E. (1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.4.576a · Cited by 42
Intractable Withdrawal From Venlafaxine Treated With Fluoxetine
Giakas, W. J., & Davis, J. M. (1997) · Psychiatric Annals · doi:10.3928/0048-5713-19970201-05 · Cited by 36
Venlafaxine withdrawal reactions
Louie, A. K., Lannon, R. A., Kirsch, M. A., & Lewis, T. B. (1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.12.1652a · Cited by 33
Venlafaxine Withdrawal Symptoms
Benazzi, F. (1996) · The Canadian Journal of Psychiatry · doi:10.1177/070674379604100722 · Cited by 26
Lithium-Induced Neurotoxicity at Serum Lithium Levels within the Therapeutic Range
Arya, D. K. (1996) · Australian & New Zealand Journal of Psychiatry · doi:10.3109/00048679609065059 · Cited by 12
Research works printed but not linked: 2
- Victorian Drug Usage Advisory Committee., 1995, Psychotropic drug guidelines
- Rosenbaum JF, 1997, Journal of Clinical Psychiatry, 58, 37
Cited by
Venlafaxine Extended-Release: A Review of its Use in the Management of Major Depression
Wellington, K., & Perry, C. M. (2001) · CNS Drugs · doi:10.2165/00023210-200115080-00007 · Cited by 263
Antidepressant Discontinuation Syndromes: Clinical Relevance, Prevention and Management
Haddad, P. M. (2001) · Drug Safety · doi:10.2165/00002018-200124030-00003 · Cited by 214
Fava, G. A., Benasi, G., Lucente, M., Offidani, E., Cosci, F., & Guidi, J. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000491524 · Cited by 209
Sarko, J. A. (2000) · Emergency Medicine Clinics of North America · doi:10.1016/s0733-8627(05)70151-6 · Cited by 117
“[46] [119] Not much is known about the metabolism of venlafaxine.”
BackgroundDiscontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment
Judge, R., Parry, M. G., Quail, D., & Jacobson, J. G. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200209000-00002 · Cited by 87
“In one report, missing a single dose of venlafaxine caused severe discontinuation symptoms within 4 h (Parker and Blennerhassett, 1998).”
Background
Metadata
- Authors
- Parker, G., & Blennerhassett, J.
- Affiliations
- UNSW Sydney (AU)
- Prince of Wales Hospital (AU)
- ORCID
- Parker, Gordon
- Venue
- Australian & New Zealand Journal of Psychiatry
- Publisher
- SAGE Publications
- Published
- 1998-04
- Volume
- 32
- Issue
- 2
- Pages
- 291-294
- ISSN
- 0004-8674 (ISSN-L)
- 1440-1614
- OpenAlex
- W2070949427
- Cited by
- 45
- References
- 14
- Citations by year
- 2021: 1 · 2018: 4 · 2015: 1 · 2014: 2 · 2013: 2
- FWCI
- 2.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Australian & New Zealand Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- venlafaxine, drug withdrawal syndrome, discontinuation syndrome, selective serotonin reuptake inhibitors, dose tapering, missed doses, hallucinations, antidepressant side effects, headache, dysphoria
- MeSH terms
- Venlafaxine Hydrochloride, Adult, Bipolar Disorder, Cyclohexanols, Depressive Disorder, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Hallucinations, Humans, Male, Risk Factors, Substance Withdrawal Syndrome, Selective Serotonin Reuptake Inhibitors, Antidepressive Agents, Second-Generation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.